The Research Working Group seeks to bridge the missing mile between basic research and the commercialization of products. Having an equal partnership between the Virtual Physiological Human Institute (VPH) and industries engaged in predictive medicine provides a unique opportunity to explore areas of mutual cooperation and benefit.

The key goals of this group are:

  • Promotion of in silico medicine in Horizon 2020;
  • Working towards the creation of a Public Private Partnership (PPP) on in silico medicine;
  • Creating links between the VPH Membership and Avicenna Industry Members


Priorities in 2018

→ Further develop a comprehensive position for Avicenna on what is needed in EU research;
→ Launch of the new Avicenna Alliance internship scheme;
→ A core focus of the VPH membership is on the FET Flagship on ageing and on shaping this Flagship programme;
→ Contribute to the three upcoming Avicenna Alliance White Papers

Working group leader:

  • Liesbet Geris
  • Executive Director, VPH Institute
  • Professor, University of Liège & KU Leuven (Belgium)

Avicenna Alliance news

EU Commission steps up support for personalised medicine

In the past months, the EU has presented several initiatives that jointly have the potential to advance personalised medicine in Europe. Next...

find out more ›

In vivo, in vitro, in silico: Why computer modelling is the next evolution of the healthcare sector

International Conference on In Silico Medicine on 4 September

find out more ›

Cipla brings India perspectives on In Silico to Brussels

New Avicenna Member company Cipla shared some key insights on India’s perspective of In Silico medicine during a visit to Brussels in April....

find out more ›

Show all activites